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Abstract
Background: C-reactive protein (CRP) and lipoprotein (a) 
(Lp[a]) play essential roles in cardiovascular disease incidence. 
This study aimed to review the association between the intake of 
conjugated linoleic acid (CLA) in the form of dietary supplement 
or enriched food with different treatment durations and the levels 
of Lp(a) and CRP in human studies.
Methods: All the articles published in Cochrane Library, ProQuest, 
Scopus, and Google Scholar from November 2014 to October 
2015 were searched and the clinical trials on the effects of CLA on 
Lp(a) and CRP levels were assessed. Of the 2249 articles initially 
retrieved, 21 eligible randomized clinical trials were enrolled in 
this systematic review. The publication dates of the eligible articles 
ranged from 2005 to 2013. The mean difference and the standard 
deviation of changes in CRP and Lp(a) levels in intervention and 
control groups were used as effect-size measures for meta-analysis. 
The obtained data from the eligible randomized controlled trials 
were meta-analyzed using Stata, version 13.
Results: The intake of CLA as a dietary supplement led to a 
significant increase in CRP levels (standardized mean difference 
[SMD]=0.41, 95% CI: 0.28 to 0.54; P=0.001). Subgroup analysis 
based on the duration of CLA consumption showed that CLA 
consumption more than 24 weeks resulted in a significant increase 
in the levels of CRP (SMD=0.52, 95% CI: 0.36 to 0.68; P=0.001) 
and Lp(a) (SMD=0.24, 95% CI: 0.01 to 0.47; P=0.04). 
Conclusion: The current systematic review and meta-analysis 
showed that the long-term consumption of CLA increases the 
levels of CRP and Lp(a).
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What’s Known
• Conjugated linoleic acid (CLA), 
prescribed as a safe nutraceutical, 
has shown efficacy against obesity, 
carcinoma, diabetes mellitus, and 
cardiovascular disease and boosts the 
immune system.
What’s New
• However, we found that CLA 
administered as a supplement 
increases C-reactive protein as a risk 
factor for cardiovascular disease. 
Review Article
Introduction
Recent studies have shown that functional foods have the potential 
to positively affect and contribute to public health. Conjugated 
linoleic acid (CLA), a fatty acid with 2 isomers, namely cis-9, 
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trans-11 (c9,t11) and trans-10, cis-12 (t10,c12), 
is considered a functional food1 and is produced 
through the hydrogenation of vegetable oils in 
industry, by bacteria residing in the rumen of 
animals, or via bioconversion in the mammary 
gland of ruminants.2 The isomers of CLA have 
demonstrated anti-obesity characteristics.3 
Furthermore, according to the latest studies on 
animals, CLA has proven to be advantageous 
both for the prevention of carcinoma, diabetes 
mellitus, and cardiovascular disease (CVD) 
and for the furtherance of body fat decrement, 
lean body mass increment, and the immune 
system.4 Research on the possible adverse 
effects of the long-term consumption of CLA 
remains to be done. CLA belongs to a subgroup 
of fatty acids entitled “trans fatty acids (TFAs)”5 
and randomized controlled trials (RCTs) have 
indicated that TFAs are detrimental to CVD risk 
factors.6
C-reactive protein (CRP) and lipoprotein (a) 
(Lp[a]) as nontraditional risk factors have been 
known to play essential roles in CVD incidence.7, 
8 A review of previous work on this subject 
reveals that there are serious discrepancies 
and controversies regarding the association 
between CLA consumption and these CVD risk 
factors.9-11 Some of these investigations have 
indicated a significant increment in Lp(a) and 
CRP levels following CLA consumption.12 
Since the RCTs on the effects of CLA 
consumption on the levels of CRP and Lp(a) have 
yielded discrepant findings, a systematic review 
and meta-analysis is necessary to settle the 
controversies and offer more reliable findings, 
especially given that commercial CLA is used 
as a safe dietary supplement and can be easily 
purchased everywhere.13 Accordingly, in the 
present study, we aimed to systematically review 
the association between CLA consumption 
in 2 distinct forms of dietary supplement and 
enriched food, with their respective different 
treatment durations, and the levels of Lp(a) and 
CRP in human studies.
Methods
Literature Search
A thorough search was conducted on all 
the articles published from November 2014 to 
October 2015 in Cochrane Library, ProQuest, 
Scopus, and Google Scholar. Additional 
records were identified through other sources, 
namely PubMed,  Science Direct, and Ovid. 
The keywords consisted of “trans-10, cis-
12-conjugated linoleic acid”, “cis-9, trans-11-
conjugated linoleic acid”, “CLA fatty acid”, “CLA”, 
“conjugated linoleic acid”, “trans fatty acid”, 
“TFA”, “C-reactive protein”, “CRP”, “lipoprotein 
(a)”, and “Lp(a)” with the medical subject 
heading [MeSH]. No restrictions were applied 
with regard to age, gender, and language during 
the search. The clinical trials investigating the 
effects of CLA (in the form of either dietary 
supplement or enriched food) on CRP or Lp(a) 
levels in healthy adults were objectively and 
meticulously assessed. The criteria for the 
inclusion of studies in the meta-analysis were 
RCT design, research on humans, healthy adult 
populations, intervention by using CLA dietary 
supplements or CLA enrichment in foods, and 
determination of serum CRP or Lp(a) levels as 
the outcome variable.  Animal studies, studies 
with any design other than CRT design, studies 
on unhealthy or non-adult individuals, studies on 
the combined effects of CLA along with other 
factors such as creatine monohydrate, and 
studies on sport were excluded. Also excluded 
were studies examining the effects of CLA on 
other outcomes or studies lacking sufficient data 
(e.g., those without control groups or baseline 
information). As the first step, the titles and 
abstracts of the articles were examined and 
relevant papers were selected. Thereafter, the 
papers were screened, sorted according to their 
titles and abstracts, and carefully reviewed. 
Data Extraction
The data of 27 articles which investigated 
the effects of CLA intake in either dietary 
supplement form or enriched food on Lp(a) and 
CRP in healthy adult populations were entered 
in the meta-analysis. However, the data of the 
following RCTs were not extracted: a study 
without complete data for analysis,14 a study 
without a placebo group,15 and 4 studies with 
unsuitable forms of CLA.16-19 Tables 1 and 2, 
respectively, provide summaries of the RCTs 
on the association between the intake of CLA 
in either dietary supplement form or enriched 
food and CVD risk factors in human studies.2, 
9, 11-12, 14, 17-36 All the information regarding the 
excluded RCTs is presented in figure 1.  The 
mean differences and standard deviations 
(SDs) for changes in Lp(a) and CRP levels 
before and after the intervention for each of the 
intervention groups and control groups were 
extracted. In addition, the mean differences 
and SDs reported for the changes in Lp(a) and 
CRP levels within each group of intervention 
and control were extracted.
Based on the consumption of CLA in either 
dietary supplement form or enriched food, 2 
subgroups were defined. The 2 subgroups were 
meta-analyzed separately. Additionally, in order to 
account for and evaluate the effects of other factors 
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such as the length of CLA dietary supplementation 
on CVD  risk factors (CRP and Lp[a]), we devised 
2 other subgroups. Furthermore, heterogeneity 
was diminished by determining and subsequently 
deleting the outlier studies based on the funnel 
plot. Therefore, 2 separate sets of data (with 
elimination and without elimination of the outlier 
studies) were included in the meta-analysis. 
The process for study selection (i.e., screening 
and eligibility), method of data extraction (i.e., 
piloted forms, independently, and in duplicate), 
listing and defining the variables, and processes 
for data obtaining and confirmation were all 
selected and done in complete accordance and 
compliance with the Preferred Reporting Items 
for Systematic Reviews and Meta-Analyses 
(PRISMA) 2009 checklist.
Risk of Bias Assessment 
The qualitative Critical Appraisal Skills 
Program (CASP) for RCTs was used to assess 
the risk of bias in the studies included in the 
review. Based on this tool, 2 screening questions 
were first used to decide whether it was worth 
proceeding to the following 8 detailed questions: 
selection bias, allocation bias, confounding, 
blinding, data collection method, withdrawal and 
dropouts, statistical analysis, and intervention 
integrity. The detailed questions were used to 
make a qualitative decision as to whether or not 
to include the study in the review. In addition, the 
quantitative 5-Point Jadad Score was applied 
to assess the quality of the relevant studies 
based on randomization, concealment of the 
treatment allocation, blinding, completeness of 
follow-up, and use of intention to treat analysis. 
Each item was given a score with a possible 
score of 0 (lowest level of quality) to 5 (highest 
level of quality). Studies with higher scores were 
considered to possess higher qualities.  
 
Statistical Analysis
All the outcomes were recorded as continuous 
variables, and pooled meta-analyses were 
completed for the studies which reported the 
same outcomes. The mean differences and SDs 
Figure 1: PRISMA flowchart shows the literature search and review.
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were combined with a Cohen random-effect 
model. The mean difference was calculated by 
subtracting the mean values before and after 
the intervention for the experimental and control 
groups. If it was not directly reported, the SD of 
the mean differences was calculated using,
where SDb=SD before, SDa=SD after, and 
r=correlation between the scores before and 
after the intervention. The correlation was 
estimated using,
where SDb, SDa, and SDc represent the 
SD for before, after, and change scores, 
respectively. The median correlation for change 
from the baseline among the trials included in 
the systematic reviews was 0.66 (interquartile 
range=0.40, 0.90).11, 21, 24, 30, 37
It was found that a simple formula:
could be used to estimate the mean by using 
the values of the median (m) and the low end 
and high end of the range (a and b, respectively). 
Additionally, the variance can be estimated via 
the formula:
38
The I2 and χ2 tests were used to assess 
heterogeneity between the studies. All the 
meta-analyses were done with the Cohen 
random-effect analysis model. Forest plots 
were applied to illustrate the results of the 
meta-analyses as well as heterogeneity in the 
results. In addition, 95% confidence intervals 
(95% CIs) were calculated for the standardized 
mean difference (SMD), and all the results were 
reported at a significance level of 0.05. The 
presence of publication bias was explored by 
constructing a funnel plot in which the estimate 
of the reported effect size was plotted against 
a measure of precision. Because an inevitable 
degree of subjectivity exists in the interpretation 
of funnel plots, the corresponding Egger’s tests 
were used to reassuringly assess the potential 
existence of publication bias. All the statistical 
analyses were conducted with Stata, version 13 
(College Station, TX, USA).
Results
Of the 2249 articles initially identified, the titles 
and abstracts of all the articles were reviewed 
to identify and select appropriate articles for 
inclusion. A total of 27 eligible RCTs were 
selected for inclusion in the analysis. Next, 
the full text of each article was reviewed and 
the findings were re-evaluated. The flowchart 
depicting the literature search and review is 
provided in figure 1.
Of the eligible articles, 4 studies were 
excluded due to the use of non-eligible forms 
of CLA.16-19 One article14 lacked inclusive data, 
and another study15 did not use a placebo 
control. Twenty-one articles were left to be 
included in the meta-analysis. Out of all the 
studies evaluating the effects of CLA intake 
in the form of either dietary supplement or 
enriched food on CRP, 12, 14, 17-23, 31, 32, 39, 40 the 
results of 7 studies indicated no significant 
change in CRP.2, 17, 18, 22, 23, 31, 32 Out of all the 
studies included in the present review on the 
effects of the CLA isomeric mixture on Lp(a), 
with the exception of 2 investigations,11, 24 
none reported a significant change in Lp(a). 
The characteristics and main outcomes of the 
RCTs are depicted in tables 1 and 2. 
CLA Intake in the Form of Dietary Supplement 
or Enriched Food and CRP
The findings of the human studies and the 
overall summary results for 15 RCTs are shown 
in figure 2. First, the analysis of the 15 RCTs 
demonstrated a significant increase in CRP 
(SMD=0.43, 95% CI: 0.22 to 0.65; P=0.001) 
with the highest heterogeneity (I2 [variation in 
the SMD attributable to heterogeneity]=67.4%, 
heterogeneity χ2=52.09 [df. =17]; P<0.001). 
Based on the funnel plot, the outlier studies2, 
21, 30 were eliminated (figure 3; funnel plot) and 
consequently the heterogeneity was reduced 
to I2=16.4%. However, the results obtained 
following the elimination, confirmed that CLA 
intake significantly increased CRP levels 
(SMD=0.30, 95% CI: 0.16 to 0.44; P<0.001). 
Further, there was no significant heterogeneity 
between the studies (I2=16.4%, heterogeneity 
χ2=16.74 [df.=14]; P=0.27) (figure 4). The studies 
were categorized based on CLA sources. The 
subgroup analysis based on CLA sources 
showed that CLA dietary supplement led to a 
significant increase in CRP levels (SMD=0.41, 
95% CI: 0.28 to 0.54; P=0.001). The subgroup 
analysis based on CLA-enriched foods showed 
that the consumption of these food items led 
to a nonsignificant increase in CRP levels 
(SMD=0.05, 95% CI:-0.22 to 0.33; P=0.7). 
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The test for heterogeneity was not statistically 
significant for the CLA dietary supplement 
subgroup (I2=3%, heterogeneity χ2=10.03 
[df.=10]; P=0.43) (figure 4) and nonsignificant 
for the CLA-enriched food subgroup (I2=0.00%, 
heterogeneity χ2=1.30 [df.=3]; P=0.73) (figure 4). 
Moreover, publication bias was found not to be 
significant (Egger’s test P=0.199).
CLA Dietary Supplementation and Lp(a)
The findings of the human studies and the 
inclusive summary results for 8 RCTs are shown 
in figure 4. CLA dietary supplementation led to a 
nonsignificant change in Lp(a) levels (SMD=0.17, 
95% CI: 0.02 to 0.32; P=0.15); the test result for 
heterogeneity was not statistically significant 
(I2=32.1%, heterogeneity χ2=16.21 [df.=11]; 
Figure 2: Meta-analysis shows a significant increase in C-reactive protein following conjugated linoleic acid supplementation. The 
black squares show study-specific standardized differences (Std diff) in means, and the horizontal lines show 95% CIs. The area 
of the black squares is proportional to the specific-study weight in the overall meta-analysis. The center of the black diamonds 
indicates the pooled standardized difference in means, and their width represents the pooled 95% CI. 
Figure 3: Funnel plot for the included studies on the effects of conjugated linoleic acid on C-reactive protein demonstrates outlier 
studies. 
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P=0.134) (figure 5). In addition, publication 
bias was found not to be weighty (Egger’s test 
P=0.446).
CLA Consumption Duration and CRP
The SMDs and 95% CIs for all the 12 
studies on the effects of CLA, irrespective of its 
Figure 4: Meta-analysis shows a significant increase in C-reactive protein following conjugated linoleic acid supplementation 
after dropping the outlier studies. The black squares show study-specific standardized differences (Std diff) in means, and the 
horizontal lines show 95% CIs. The area of the black squares is proportional to the specific-study weight in the overall meta-
analysis. The center of the black diamonds indicates the pooled standardized difference in means, and their width represents the 
pooled 95% CI.
Figure 5: Meta-analysis shows no significant change in lipoprotein (a) following conjugated linoleic acid supplementation. The 
black squares show study-specific standardized differences (Std diff) in means, and the horizontal lines show 95% CIs. The area 
of the black squares is proportional to the specific-study weight in the overall meta-analysis. The center of the black diamonds 
indicates the pooled standardized difference in means, and their width represents the pooled 95% CI. 
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consumption in the form of dietary supplement 
or enriched food, on CRP are presented in 
figure 5. CLA consumption greatly increased 
CRP levels (SMD=0.30, 95% CI: 0.16 to 0.44; 
P=0.001). There was significant heterogeneity 
between the studies (I2=16.4%, heterogeneity 
χ2=16.74 [df.=14]; P<0.27) (figure 6). The studies 
were categorized based on the duration of CLA 
consumption. The subgroup analysis based on 
CLA consumption periods of less than 24 weeks 
indicated a nonsignificant rise in CRP levels 
(SMD=0.15, 95% CI: -0.02 to 0.32; P=0.08). The 
subgroup analysis based on the duration of CLA 
consumption demonstrated that CLA intake with 
regard to time intervals longer than 24 weeks 
led to a consequential increase in CRP levels 
(SMD=0.52, 95% CI: 0.36 to 0.68; P=0.001). 
The test for heterogeneity was not statistically 
notable for the subgroup with CLA consumption 
durations of more than 24 weeks (I2=00.0%, 
heterogeneity χ2=1.29 [df.=3]; P=0.73) and 
nonsignificant for CLA consumption durations 
of less than 24 weeks (I2=0.00%, heterogeneity 
χ2=5.67 [df.=10]; P=0.84) (figure 5). In addition, 
publication bias was found not to be considerable 
(Egger’s test P=0.199).
CLA Consumption Duration and Lp(a)
The SMDs and 95% CIs for all the 7 studies 
on the effects of CLA consumption in the form 
of dietary supplement on Lp(a) are outlined 
in figure 7. CLA consumption did not confer a 
significant boost to Lp(a) levels (SMD=0.14, 95% 
CI: -0.05 to 0.26; P=0.15). In addition, there was 
no significant heterogeneity among the studies 
(I2=32.1%, heterogeneity χ2=16.21 [df.=11]; 
P=0.13) (figure 7). The studies were categorized 
based on the duration of CLA consumption. 
Next, the subgroup analysis done on the basis of 
the duration of CLA consumption demonstrated 
that CLA supplementation for periods longer 
than 24 weeks led to a considerable increase 
in Lp(a) levels (SMD=0.24, 95% CI: 0.01 to 
0.47; P=0.04). The test for heterogeneity was 
not statistically significant for the subgroups 
with CLA consumption for longer than 24 
weeks (I2=41.9%, heterogeneity χ2=6.88 [df.=4]; 
P=0.14). On the other hand, the subgroup 
analysis based on CLA consumption periods of 
less than 24 weeks showed that the consumption 
of these food items resulted in a nonsignificant 
decrease in Lp(a) levels (SMD=-0.04, 95% CI: 
-0.35 to 0.26; P=0.37). Additionally, there was 
no noteworthy heterogeneity for subgroups with 
CLA consumption periods of less than 24 weeks 
(I2=6.7%, heterogeneity χ2=6.43 [df.=6]; P=0.37) 
(figure 7). Finally, publication bias was found not 
to be consequential (Egger’s test P=0.446).
Figure 6: Meta-analysis shows a significant increase in C-reactive protein after conjugated linoleic acid supplementation for more 
than 24 weeks. The black squares show study-specific standardized differences (Std diff) in means, and the horizontal lines show 
95% CIs. The area of the black squares is proportional to the specific-study weight in the overall meta-analysis. The center of the 
black diamonds indicates the pooled standardized difference in means, and their width represents the pooled 95% CI. 
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Discussion
The present systematic review and meta-
analysis of RCTs concluded that CLA intake and 
particularly CLA dietary supplements notably 
increased CRP levels. In accordance with 
the findings of the present meta- analysis, the 
results of several studies have asserted and 
justified the significant increases in CRP levels 
following CLA consumption, particularly in the 
form of commercial dietary supplements.12, 14, 
19-21, 39, 40 Nonetheless, there are some RCTs in 
the existing literature reporting no considerable 
impact.7, 18, 22, 23, 31, 32 The findings of some 
studies have exhibited significant gains in 
CRP levels following t10,c12 CLA isomer 
supplementation.41, 42 Moreover, the findings 
of some of the reviewed studies showed that 
the differences in the proportion of the isomers 
of CLA (c9,t11 and t10,c12) did not control the 
impact of CLA consumption on CRP. Numman 
and colleagues31 and Remark and colleagues32 
examined 2 different proportions of 2 of the most 
abundant isomers of CLA (c9,t11 and t10,c12) 
on CRP in a group of participants and found no 
notable variations. We assume that other factors 
such as genetic predisposition, gender, and 
duration of CLA administration might account 
for and explain the incongruous findings having 
been reported in different studies. Abdelmagid 
and colleagues43 showed that the plasma 
concentration of CLA was influenced by stearoyl-
CoA desaturase 1 (SCD1) genetic variations and 
hormonal status. It has been reported that the 
circulating CLA concentration is significantly 
higher in women than in men.43 It could be 
concluded that even a modest amount of t10,c12 
CLA induces considerable inflammatory effects 
in humans. The duration of CLA administration 
might also explain the inconsistencies in findings 
and address the posited discrepancies. Our 
subgroup meta-analysis based on the duration of 
the intervention illustrated that CLA consumption 
for periods of 24 weeks or longer increased CRP 
levels. 
The specific intricate mechanism which 
accounts for the impact of CLA consumption 
on CRP is still ambiguous and requires further 
research. Steck and colleagues21 reported that 
higher dosages of CLA dietary supplements 
might give rise to inflammatory markers in 
healthy obese adults. Consistently, CLA 
dietary supplementation in human subjects has 
increased the 15-keto-dihydro-PGF2a urine 
level, a marker of cyclooxygenase-catalyzed 
lipid peroxidation. It should be borne in mind 
that increases in CRP and 15-keto-dihydro-
PGF2a are correlated.30 On the other hand, CLA 
has at least a trans double bond and belongs 
to the TFA group.44 The relationship between 
TFA and inflammation is clear and can be found 
elsewhere.45 CRP is an acute-phase protein 
Figure 7: Meta-analysis shows a significant increase in lipoprotein (a) after conjugated linoleic acid supplementation for more than 
24 weeks. The black squares show study-specific standardized differences (Std diff) in means, and the horizontal lines show 95% 
CIs. The area of the black squares is proportional to the specific-study weight in the overall meta-analysis. The center of the black 
diamonds indicates the pooled standardized difference in means, and their width represents the pooled 95% CI.
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produced by the liver up to 1000 times through 
inflammation. It is more sensitive to inflammatory 
cytokines than other acute-phase proteins.46 
Therefore, a rise in CRP levels after an increase 
in CLA levels in circulation is expectable. 
We observed no significant increase in 
Lp(a) concentration following CLA dietary 
supplementation in RCTs. However, when we 
categorized the studies based on the duration 
of CLA consumption, the subgroup analysis 
demonstrated that CLA supplementation 
for periods longer than 24 weeks led to a 
consequential increase in Lp(a) levels. The 
results obtained through our analysis proved to 
be in complete accordance with the findings of 
5 other studies12, 23, 25-27 and in discordance with 
2 others.11, 24 The duration of CLA consumption 
can explain the discrepancy between the 2 
groups of studies. Gaullier and colleagues,11, 24 
in 2004 and 2005, used various forms of CLA 
mixtures in healthy overweight subjects for 1 and 
2 years, respectively, and concluded that CLA 
supplementation was able to increase the level of 
Lp(a). Nevertheless, in another study conducted 
in 2007, Gaullier and colleagues12 used CLA-TAG 
over a 6-month interval in healthy overweight 
and obese subjects and found no differences 
in Lp(a) levels between the CLA group and the 
placebo group. Similarly, other studies with 
durations of CLA supplementation for 4 weeks,23 
12 weeks,25, 26 and 24 weeks12 found no effect on 
Lp(a). In the studies conducted by Gaullier and 
colleagues, which took place over a period longer 
than 1 year, Lp(a) increment was accompanied 
by increases in leukocytes and thrombocytes, 
suggesting an inflammatory and immunological 
response to CLA supplementation. However, the 
precise process and functioning are still not fully 
clear and require further research.  
In humans, no limits on safety parameters 
(duration, dosage, variety, etc.) have been 
reported with CLA consumption. Studies on 
overweight or obese adults, with different doses 
of CLA (i.e., 1.7, 3.4, 5.1, and 6.8 g/d) and 
durations (i.e., 4, 8, 12, 36, 48 weeks and more), 
have been conducted.28-30, 33-36 A consensus 
should emerge on the usage of CLA and the 
upper limit for this functional food. 
The major strength of the present study lies 
in its analysis of CLA dietary supplements and 
CLA-enriched foods in separation of one another. 
Moreover, consideration and examination of 
biases, with specific focus on publication bias, 
can be pointed out as another decisive and 
differentiating strength of the current study.
As for the potential limitations or shortcomings 
of the present study, we note that the current 
meta-analysis strives to reconcile the conflicting 
results previously reported and merely reflects 
the existing evidence. Furthermore, deficiencies 
which have their roots in the design, conduct, 
analysis, and interpretation of the research, 
along with the ability to identify sources of 
diversity across various types of studies have 
served as another source of limitation. 
It is important to bear in mind, however, that 
in general, not only is meta-analyses unable 
to improve the quality of the original studies or 
address the variability of patient populations, but 
also they are incapable of enhancing the quality 
of the data and diminishing the potential for the 
underlying biases.
Conclusion
The current systematic review and meta-
analysis of randomized placebo-controlled 
trials illustrated that CLA in the form of dietary 
supplement greatly affects some CVD risk 
factors such as CRP and Lp(a). Nonetheless, 
the length of intervention is a determining factor 
in the safety of the CLA consumer. We conclude 
that the long-term consumption of CLA increases 
CRP and Lp(a) levels.
Since CLA has long been widely present in 
various diets and also in commercial dietary 
supplements, long-term trials with different 
doses of CLA on various patient populations 
are deemed essential to attest the safety of 
commercial CLA dietary supplements, endorse 
their use, and ensure the absence of any adverse 
impact or danger to human health. 
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